List view / Grid view
15 July 2016 | By Victoria White, Digital Content Producer
Celgene’s Revlimid (lenalidomide) has been approved by the EC for the treatment of adult patients with relapsed or refractory mantle cell lymphoma...
7 July 2016 | By Victoria White, Digital Content Producer
The EC has granted an extension of the Market Authorisation for Revestive for the treatment of patients aged one year and above with Short Bowel Syndrome...
6 July 2016 | By Victoria White, Digital Content Producer
The EC has extended the current conditional marketing authorisation of Adcetris as consodlidation treatment in post-transplant Hodgkin lymphoma...
5 July 2016 | By Victoria White, Digital Content Producer
The approval of Zinbryta is supported by results from two studies, including DECIDE, the largest and longest head-to-head Phase III study ever conducted in MS...
4 July 2016 | By Victoria White, Digital Content Producer
The EC has approved a variation to the marketing authorisation for Amgen’s Kyprolis (carfilzomib) to include use in combination with dexamethasone alone...
28 June 2016 | By Victoria White, Digital Content Producer
The EC has granted marketing authorisation for Zavicefta for the treatment of patients with serious Gram-negative bacterial infections...
23 June 2016 | By Victoria White, Digital Content Producer
The EC has granted marketing authorisation for Gilead’s once-daily single tablet regimen Odefsey for the treatment of HIV-1 infection in certain patients...
The European Commission has approved Roche’s Gazyvaro (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance in people with follicular lymphoma.
8 June 2016 | By Victoria White, Digital Content Producer
The combination is approved for the first-line treatment of adult patients with non-squamous NSCLC with EGFR-activating mutations...
2 June 2016 | By Victoria White, Digital Content Producer
The EC has approved Afinitor (everolimus) for the treatment of neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease...
1 June 2016 | By Victoria White, Digital Content Producer
The EC has approved the use of Trevicta (paliperidone palmitate a 3-monthly injection) for the maintenance treatment of schizophrenia in adult patients...
The EC has approved the subcutaneous formulation of MabThera for people with previously untreated and relapsed/refractory chronic lymphocytic leukaemia...
31 May 2016 | By Victoria White, Digital Content Producer
The European Commission (EC) has approved Imbruvica (ibrutinib) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
12 May 2016 | By Victoria White, Digital Content Producer
Empliciti (elotuzumab) is approved for use with Revlimid (lenalidomide) and dexamethasone in patients who have received at least one prior therapy...
11 May 2016 | By Victoria White, Digital Content Producer
The approval of Opdivo + Yervoy represents the first and only approved combination of two Immuno-Oncology agents in the European Union (EU)...
